PMID- 31090656
OWN - NLM
STAT- MEDLINE
DCOM- 20200618
LR  - 20240229
IS  - 1537-4513 (Electronic)
IS  - 1524-9557 (Linking)
VI  - 42
IP  - 5
DP  - 2019 Jun
TI  - Incidence and Clinical Impact of Anti-TNFalpha Treatment of Severe Immune Checkpoint 
      Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
PG  - 175-179
LID - 10.1097/CJI.0000000000000268 [doi]
AB  - Immune checkpoint inhibitors (ICI) significantly improve overall survival (OS) in 
      patients with advanced melanoma, but immune-related colitis may occur and warrant 
      anti-tumor necrosis factor alpha (TNFalpha) treatment in severe forms. A nationwide, 
      multicenter retrospective survey was conducted to assess both, the real-life 
      incidence of grade 3/4 ICI-induced colitis treated with anti-TNFalpha, in patients 
      with advanced melanoma, and the consequence of this therapeutic strategy on 
      disease outcome. All patients with advanced melanoma treated with anti-TNFalpha 
      agents for severe ICI-related colitis in the participating centers were included. 
      Relative incidence was calculated according to the total number of patients 
      treated with ICI in network centers during the period of inclusion. The possible 
      impact of anti-TNFalpha treatment on disease outcome was evaluated through comparison 
      of objective response rate, progression-free survival, and OS with pivotal 
      literature data. Twenty-seven patients from 13 tertiary referral centers were 
      included. Overall, severe ICI-related colitis treated with anti-TNFalpha occurred in 
      1% of patients with advanced melanoma, mostly with ipilimumab. Infliximab was 
      successfully used in all patients but 1, mostly after 1 infusion. OS and 
      progression-free survival of 12 and 3 months, respectively, were observed in 
      these patients, along with an objective response rate of 41% at 12 months. This 
      survey shows a low real-life incidence of severe colitis requiring anti-TNFalpha. 
      Response rates to immunotherapy and survival data do not appear to significantly 
      differ from those observed in pivotal studies. Severe ICI-induced colitis 
      requiring anti-TNFalpha treatment appears to be a rare event in advanced melanoma, 
      and infliximab does not seem to adversely affect disease outcome.
FAU - Lesage, Candice
AU  - Lesage C
AD  - Department of Dermatology, University Hospital.
FAU - Longvert, Christine
AU  - Longvert C
AD  - Department of Dermatology, Ambroise-Pare Hospital, APHP, Boulogne-Billancourt.
FAU - Prey, Sorilla
AU  - Prey S
AD  - CHU, Bordeaux, Department of Dermatology.
AD  - Inserm U-1035, University of Bordeaux, Bordeaux.
FAU - Maanaoui, Sarah
AU  - Maanaoui S
AD  - Department of Dermatology, University Hospital, Lille.
FAU - Dreno, Brigitte
AU  - Dreno B
AD  - Department of Dermatology, University Hospital, Nantes.
FAU - Machet, Laurent
AU  - Machet L
AD  - Department of Dermatology, CHRU Tours and Inserm U1253, University of Tours, 
      Tours.
FAU - Zehou, Ouidad
AU  - Zehou O
AD  - Department of Dermatology, University Hospital Henri Mondor, Creteil.
FAU - Kramkimel, Nora
AU  - Kramkimel N
AD  - Department of Dermatology, University Hospital Cochin, Paris.
FAU - Jeudy, Geraldine
AU  - Jeudy G
AD  - Department of Dermatology, University Hospital, Dijon.
FAU - Skowron, Francois
AU  - Skowron F
AD  - Department of Dermatology, Hospital, Valence.
FAU - Aubin, Francois
AU  - Aubin F
AD  - Department of Dermatology, University Hospital, Besancon.
FAU - Visseaux, Laetitia
AU  - Visseaux L
AD  - Department of Dermatology, University Hospital Robert Debre, Reims.
FAU - Mansard, Sandrine
AU  - Mansard S
AD  - Department of Dermatology, University Hospital Estaing, Clermont Ferrand, France.
FAU - Dereure, Olivier
AU  - Dereure O
AD  - Department of Dermatology, University Hospital.
FAU - Lesage, Francois-Xavier
AU  - Lesage FX
AD  - Epsylon, University Montpellier, Paul Valery University Montpellier 3, University 
      Hospital, Montpellier.
FAU - Guillot, Bernard
AU  - Guillot B
AD  - Department of Dermatology, University Hospital.
CN  - French Group of Onco-Dermatology
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents, Immunological/*adverse effects/therapeutic use
MH  - Biomarkers, Tumor
MH  - Colitis/diagnosis/*epidemiology/*etiology
MH  - Colonoscopy
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Melanoma/*complications/drug therapy/*epidemiology/pathology
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
EDAT- 2019/05/16 06:00
MHDA- 2020/06/19 06:00
CRDT- 2019/05/16 06:00
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2020/06/19 06:00 [medline]
AID - 00002371-201906000-00003 [pii]
AID - 10.1097/CJI.0000000000000268 [doi]
PST - ppublish
SO  - J Immunother. 2019 Jun;42(5):175-179. doi: 10.1097/CJI.0000000000000268.